921 Impact of HIV Protease Inhibitors on the Treatment of HIV-Infected Tuberculosis Patients with Rifampin; 926 AIDS Rates

MMWR Morbidity and Mortality Weekly Report, October 25, 1996/Vol. 45/No. 42
Centers for Disease Control and Prevention

SUMMARY: 921 In 1995 and 1996, the Food and Drug Administration (FDA) approved three products in the new protease inhibitor class of drugs--saquinavir (Invirase), ritonavir (Norvir), and indinavir (Crixivan). Another drug in this class of agents, nelfinavir (Viracept)(Agouron Pharmaceuticals), is expected to be available soon from the manufacturer through an expanded-access program. All four drugs, which inhibit HIV protease and thus interfere with viral maturation and replication, are the most potent antiretroviral agents available to treat patients with HIV disease.

926The following map provides information about the reported number of acquired immunodeficiency syndrome (AIDS) cases per 100,000 population, by state of residence from July 1995 through June 1996. The accompanying table lists the metropolitan areas with the 50 highest annual rates of AIDS per 100,000 population.

NOTE: MMWR's are in Portable Document Format (PDF) to retain the original format. To view or print these documents, you must use the Adobe Acrobat viewer. Acrobat is free and available directly from Adobe's website with full installation instructions. Get Adobe Acrobat

Download MM4542.PDF
961025
MM4542

Always watch for outdated information. This article first appeard in 1996. This material is designed to support, not replace, the relationship that exists between you and your doctor.

Copyright © 1996 - MMWR. Reproduced with permission. Morbidity and Mortality Weekly Report is published every Friday by the Centers for Disease Control and Prevention, U.S. Department of Health and Human Services. Noncommercial reproduction is encouraged.  http://www.cdc.gov

This information is designed to support, not replace, the relationship that exists between you and your doctor.
©1998. AEGIS.